←
Psychedelic Alpha7,717 posts
Psychedelic Alpha avatar

Psychedelic Alpha

@Psyched_Alpha

The leading independent, data-driven voice in psychedelics.

◷ Joined April 2020▧ 1,410 Photos and videos
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·1h

Now underway: lawmakers on the House Veterans’ Affairs Subcommittee on Health are hearing from VA officials and expert witnesses on how psychedelic-assisted therapies could be rolled out in the system.

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·4h

Speaking at Jefferies Global Healthcare Conference in London this morning, Compass Pathways $CMPS Chief Commercial Officer Lori Englebert responded to a question about Usona Institute's psilocybin for major depressive disorder (MDD) program. To start, Englebert picked at elements of the nonprofit's Phase 3 trial design, which she said is not compatible with FDA's recent final guidance for psychedelic trials.

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·4h

Speaking at Jefferies Global Healthcare Conference in London this morning, Compass Pathways $CMPS CEO Kabir Nath responded to a question about Usona Institute's psilocybin for major depressive disorder (MDD) program. There, he said that Compass believes that Usona infringes its intellectual property and said that, should the nonprofit secure approval, the company "would take appropriate measures."

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·4h

“There are clinical trials that have been ongoing with group therapies or group treatments. That’s going to be essential to be able to scale these things much more quickly and deliver more treatments to our veterans faster. Those are things that we've experimented with and we’re continuing to tinker with.” Andrew Gradison, Senior Advisor, U.S. Department of Veterans Affairs, speaking at The Psychedelic Healthcare Forum.

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 17

“I think the state models are performing a valuable function in terms of generating real-world data. I think the jury’s out as to whether they’re going to exist 10 years from now. If you go to the state models, it’s not going to be covered by insurance, so you’re paying cash out of pocket. With an FDA-approved medicine, hopefully there’s insurance coverage, so it might be cheaper if you have one of the labelled indications.” Matt Zorn, Deputy General Counsel, U.S. Department of Health and Human Services, speaking at The Psychedelic Healthcare Forum.

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 17

Three Psychedelics New Drug Applications now sit before the FDA, with potential decisions in the coming months and, in the case of approvals, launches next year. Here, our Editor @Josh__Hardman briefly walks you through each program.

5:00
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 17

Ibogaine drug developer Soneira announced today that it has completed dosing of the first cohort of healthy volunteers in a Phase I study of its oral ibogaine candidate, SON-001. The study is being conducted in Canada, and the company hopes it will support future development of the candidate in the treatment of disabilities associated with traumatic brain injury (TBI).

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 17

GAO Calls on DEA and FDA to Develop Scheduling Policies A new report by the U.S. Government Accountability Office (GAO) recommends that both FDA and DEA improve their scheduling policies. “For example, DEA does not have policies that identify roles, responsibilities, and procedures”, it writes. “Additionally, FDA doesn’t specify how its staff are to conduct evaluations or develop recommendations”, it goes on.  Only a small part of the report focuses on rescheduling decisions that are responsive to new drug applications. Read more on our website: psychedelicalpha.com/news/p%…

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 16

NRx Planned to Market Ketamine for Depression at $500-1,000 Per Dose According to a 2024 investor presentation, NRx Pharmaceuticals had planned to price its preservative-free ketamine at $500-$1,000 per dose if it were able to get it on-label for depression, citing Spravato as a benchmark. For now, it only has an FDA label for anaesthesia, following FDA approval last month. Read more on our website: psychedelicalpha.com/news/p%…

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 16

This morning, Helus Pharma (formerly Cybin) announced a positive topline readout from its first Phase 3 study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD). In our latest, we provide breaking coverage and analysis. Read our breaking coverage: psychedelicalpha.com/news/br…

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 16

Podcast: Compass Files Psilocybin Application with FDA, U.S. Government Taps Mark Cuban to Develop Ibogaine, Psychedelics After the Midterms In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories: • Compass Pathways submits its psilocybin new drug application to FDA • We look at what the midterms might mean for the psychedelics field • U.S. government taps Mark Cuban to support ibogaine research push • Delix Therapeutics raises $100M Series C • Other stories Listen on our website or on your favourite podcast app: psychedelicalpha.com/news/po…

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 14

The U.S. House Veterans’ Affairs Subcommittee on Health is set to hold an oversight hearing titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward” on Wednesday, November 18th.  The hearing comes after the Department of Health and Human Services (HHS) committed up to $4.9 million to develop ibogaine for PTSD, via ARPA-H.

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 13

GH Research Pushes Phase 3 Start to 2027, Drops Individualised Dosing 5-MeO-DMT drug developer GH Research no longer expects to start its pivotal program of GH001 in treatment-resistant depression in 2026, it revealed this morning. The company had guided to a 2026 start since mid-2025, and reaffirmed that timeline as recently as August. But its Q3 update, released today, points to an End-of-Phase II meeting with FDA in Q1 2027, with initiation “shortly after”, subject to final alignment. The design has changed, too: the company is dropping the individualised dosing regimen used in its Phase 2b in favour of fixed doses, with one dose per treatment visit.

Post attachment
Psychedelic Alpha avatar
Psychedelic Alpha@Psyched_Alpha·Nov 13

Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA In this Field Note, Josh shares notes from a recent trip to Washington, D.C., where he attended BrainFutures’ Frontiers of Mental Health and Recovery. Topics include: • Three psychedelic NDAs now with FDA and views on psilocybin packages • ICER’s review of Compass’ psilocybin, and what its Spravato precedent suggests • CDER Director Mike Davis on FDA’s role (and its limits) in psychedelics • Washington’s shifting politics, from the midterms to FDA leadership • This week’s HHS ibogaine announcement, NIMH’s funding opportunity, and Delix’s J&J-backed raise Listen now on our website: psychedelicalpha.com/news/fi…

Post attachment